Corentec Co

Corentec Co Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Corentec Co (104540.KQ) as of Nov 6, 2026 is 138.71. In the previous year, Cash Conversion Cycle (CCC) was 420.87 — a change of -67.04% (lower).

Cash Conversion Cycle

138.71

YoY

-67.04%

Last updated:

Cash Conversion Cycle (CCC) of Corentec Co is 2025 138.71 . Cash Conversion Cycle (CCC) of Corentec Co was 2024 420.87 . It decreases by -67.04% lower compared to the previous year.

The Corentec Co Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
501.22 KRW
Jan 1, 2019
467.14 KRW
Jan 1, 2020
606.24 KRW
Jan 1, 2021
615.23 KRW
Jan 1, 2022
392.22 KRW
Jan 1, 2023
343.58 KRW
Jan 1, 2024
420.87 KRW
Jan 1, 2025
138.71 KRW
The Corentec Co Cash Conversion Cycle history
YEARCash Conversion CycleYoY
138.71-67.04%
420.87+22.50%
343.58-12.40%
392.22-36.25%
615.23+1.48%
606.24+29.78%
467.14-6.80%
501.22-13.27%
577.92+3.41%
558.86-11.54%
631.78+17.82%
536.20—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Corentec Co Stock analysis

What does Corentec Co do? Corentec Co., Ltd. manufactures and sells artificial articulations, including hip, knee, and spine products. The company offers hip products under the BENCOX brand, featuring primary systems, hemi-arthroplasty systems, and revision systems such as cementless femoral stems and acetabular cups. Knee products are sold under the LOSPA brand, including fixed and mobile primary knee systems and revision systems. Spine products also carry the LOSPA IS brand, comprising pedicle screws and peek cages. Corentec distributes these products domestically and internationally, targeting healthcare providers and hospitals that require orthopedic solutions. The firm’s revenue comes from the sale of hip, knee, and spine products through its BENCOX, LOSPA, and LOSPA IS brand portfolios. Domestic and overseas markets are key segments, with the company focusing on orthopedic surgeons and medical institutions that purchase these specialized medical devices. Corentec’s product lines are designed for both primary and revision surgeries, catering to a broad range of orthopedic needs in the healthcare sector. Corentec Co., Ltd. serves healthcare providers globally, with its BENCOX brand dominating hip product sales and LOSPA/LOSPA IS covering knee and spine solutions. The company’s distribution strategy emphasizes direct sales to hospitals and medical centers, ensuring consistent product availability for surgical procedures. By maintaining distinct brand identities for each product category, Corentec efficiently targets specific medical specialties within the orthopedic market. Corentec Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Corentec Co stock

Cash Conversion Cycle (CCC) of Corentec Co is 138.71 in 2025.

Cash Conversion Cycle (CCC) of Corentec Co changed from 420.87 to 138.71, representing a -67.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Corentec Co since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Corentec Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Corentec Co

All Key Metrics — Corentec Co